Skip to main content
. 2021 Jun 19;43(2):199–239. doi: 10.1210/endrev/bnab019

Table 9.

Follow-up of asymptomatic cluster 2-mutation carriers

Follow-up of asymptomatic mutation carriers RET NF1
Clinical and biochemical evaluation Initial screening by the age of 11-16 years depending on the specific mutation, then every 12 months (higher penetrance)
Risk of primary hyperparathyroidism and medullary thyroid carcinoma (every 12 months calcitonin, calcium, PTH if applicable)
Initial screening by the age of 10-14 years, then every 36 months (lower penetrance)